Axonics Modulation Technologies Stock News

Axonics (AXNX) delivered earnings and revenue surprises of 17.54% and 16.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Here is how Axonics Modulation Technologies (AXNX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct

Here is how Axonics Modulation Technologies (AXNX) and Bellus Health (BLU) have performed compared to their sector so far this year.

Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.

Axonics is a high-growth medical device play with strong revenue growth drivers. The company's rechargeable SNM system generates the vast majority of its sales.

Axonics, Inc. (NASDAQ:AXNX ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - Presi

Axonics (AXNX) delivered earnings and revenue surprises of 27.54% and 7.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

The FDA has approved Axonics Inc''s (NASDAQ: AXNX ) recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). The Axonics F15 recharge-free SNM system''s functional life has been validated for over 15 years at typical stimulation parameters and … Full story available on Benzinga.com

Some of the stocks that may grab investor focus today are: Wall Street expects Dick''s Sporting Goods, Inc. (NYSE: DKS ) to report quarterly earnings at $3.43 per share on revenue of $3.29 billion before the opening bell. Dick''s Sporting shares gained 1.5% to $101.00 in pre-market trading. Axonics, Inc. (NASDAQ: AXNX ) said it has received the FDA approval for recharge-free sacral neuromodulation implantable neurostimulator. Axonics shares gained 1.6% to $55.00 in the … Full story available on Benzinga.com

Axonics Modulation Technologies press release (AXNX): Q4 GAAP EPS of -$0.34 beats by $0.02.Revenue of $53.1M (+52.6% Y/Y) beats by $2.58M.

Axonics, Inc. (AXNX) CEO Raymond Cohen on Q4 2021 Results - Earnings Call Transcript

Axonics (AXNX) delivered earnings and revenue surprises of 5.56% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct